ASCO 2022 | Ponatinib in advanced GISTs

Michael C. Heinrich, MD, OHSU Knight Cancer Institute, Portland, OR, discusses the results of a Phase II study evaluating ponatinib in patients with advanced gastrointestinal stromal tumors (GISTs). This single-arm phase II trial enrolled patients with metastatic and/or unresectable GIST with failure of prior tyrosine kinase inhibitor (TKI) treatment into two cohorts based on the presence or absence of KIT exon 11 (ex11) primary mutations. Ponatinib demonstrated some activity in advanced GIST, particularly in KIT ex11-positive disease, however, significance is not enough to warrant further investigation. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.